asco 2021 lung recap: codebreak 100: sotorasib in kras g12c mutation
Published 2 years ago • 1K plays • Length 5:26Download video MP4
Download video MP3
Similar videos
-
6:10
asco 2021 lung recap: circulatory tumor dna
-
12:25
adagrasib for previously treated kras g12c nsclc - asco lung review 2022
-
6:33
sotorasib for kras g12c-mutated lung cancer
-
4:13
sotorasib vs. adagrasib as treatment for kras g12c mutated nsclc - case based panel discussion
-
8:08
asco 2021 lung recap: mylung consortium: overall biomarker testing
-
7:39
chemotherapy and immunotherapy for patients with kras mutations - asco lung review 2022
-
8:13
asco 2021 lung recap: fda analysis of immunotherapy with or without chemo in adv nsclc and low pdl-1
-
6:38
asco 2021 lung recap: poseidon trial: durvalumab /- tremelimumab vs. chemo alone
-
5:35
progression on sotorasib with kras nsclc - 2022 program: targeted therapies forum
-
3:01
phase ii codebreak 100 trial of sotorasib in advanced nsclc
-
5:27
asco 2021 lung recap: lurbinectedin in small cell lung cancer and the failed atlantis trial
-
1:26
krystal-1 and codebreak 100: targeting kras g12c in lung cancer
-
6:28
codebreak 100: sotorasib in kras-mutated nsclc
-
2:32
codebreak 100: patient-reported outcomes evaluating sotorasib in kras p.g12c mnsclc
-
2:35
#esmo22 highlights on sotorasib in nsclc with kras g12c mutation: the codebreak 200 study
-
11:30
asco 2021 lung recap: surgical outcomes & checkmate 816: nivolumab in early stage nsclc
-
2:52
kras-mutant nsclc: codebreak 100 trial of sotorasib
-
1:17
codebreak100: assessing sotorasib in patients with kras p.g12c-mutant pancreatic cancer